serine peptidase inhibitor, Kunitz type 5, pseudogeneGenealiases: C20orf168 · dJ447F3.6
Q-omics provides the consensus-scored SPINT5P profile across patient tissues and cancer cell-line models. SPINT5P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPINT5P is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, SPINT5P RNA expression shows 12,387 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, ESCA, and LSCC as cancer lineages where SPINT5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPINT5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPINT5P survival associations across molecular data types. SPINT5P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPINT5P RNA expression–survival associations across cancer types. High SPINT5P expression shows unfavorable associations in KIRC, CESC, MESO, LGG and GBM, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPINT5P RNA expression.
This table summarizes SPINT5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPINT5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPINT5P shows higher tumor expression in ESCA. The ESCA box plot shows higher SPINT5P RNA expression in tumor versus normal tissue (log2 FC = +0.815, t-test p = .026).
This table shows molecular features associated with SPINT5P in patient tissues and cancer cell lines. In patient samples, SPINT5P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
